Avoid Transvenous Leads in Appropriate Subjects
To evaluate whether a subcutaneous implantable cardioverter defibrillator (ICD) reduces perioperative complications compared to a transvenous ICD, using a composite safety outcome.
This study is a multi-centre, randomized, open-label parallel group clinical trial.
The primary safety endpoint will be measured at 6 months following ICD implantation, and will be a composite of lead-related perioperative complications.
Angie Djuric, Andrea Ling